MX2022009254A - Dosificacion y metodos para tratar la hipertension arterial pulmonar. - Google Patents
Dosificacion y metodos para tratar la hipertension arterial pulmonar.Info
- Publication number
- MX2022009254A MX2022009254A MX2022009254A MX2022009254A MX2022009254A MX 2022009254 A MX2022009254 A MX 2022009254A MX 2022009254 A MX2022009254 A MX 2022009254A MX 2022009254 A MX2022009254 A MX 2022009254A MX 2022009254 A MX2022009254 A MX 2022009254A
- Authority
- MX
- Mexico
- Prior art keywords
- rodatristat
- ethyl
- sub
- combination
- pah
- Prior art date
Links
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical compound CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 title abstract 10
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 title abstract 6
- 229940121489 rodatristat Drugs 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000002207 metabolite Substances 0.000 abstract 3
- 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 abstract 2
- 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 abstract 2
- 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 abstract 2
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 abstract 2
- 102100026533 Cytochrome P450 1A2 Human genes 0.000 abstract 2
- 102100029363 Cytochrome P450 2C19 Human genes 0.000 abstract 2
- 102100029358 Cytochrome P450 2C9 Human genes 0.000 abstract 2
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- 230000001747 exhibiting effect Effects 0.000 abstract 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 abstract 2
- 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 abstract 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 abstract 1
- 102100038739 Cytochrome P450 2B6 Human genes 0.000 abstract 1
- 102100039205 Cytochrome P450 3A4 Human genes 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 229960002414 ambrisentan Drugs 0.000 abstract 1
- OUJTZYPIHDYQMC-LJQANCHMSA-N ambrisentan Chemical compound O([C@@H](C(OC)(C=1C=CC=CC=1)C=1C=CC=CC=1)C(O)=O)C1=NC(C)=CC(C)=N1 OUJTZYPIHDYQMC-LJQANCHMSA-N 0.000 abstract 1
- 229960003065 bosentan Drugs 0.000 abstract 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 abstract 1
- 230000008406 drug-drug interaction Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003116 impacting effect Effects 0.000 abstract 1
- 229960001039 macitentan Drugs 0.000 abstract 1
- JGCMEBMXRHSZKX-UHFFFAOYSA-N macitentan Chemical compound C=1C=C(Br)C=CC=1C=1C(NS(=O)(=O)NCCC)=NC=NC=1OCCOC1=NC=C(Br)C=N1 JGCMEBMXRHSZKX-UHFFFAOYSA-N 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 229960003841 selexipag Drugs 0.000 abstract 1
- QXWZQTURMXZVHJ-UHFFFAOYSA-N selexipag Chemical compound C=1C=CC=CC=1C1=NC(N(CCCCOCC(=O)NS(C)(=O)=O)C(C)C)=CN=C1C1=CC=CC=C1 QXWZQTURMXZVHJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960003310 sildenafil Drugs 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 229960000835 tadalafil Drugs 0.000 abstract 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 abstract 1
- 229960005032 treprostinil Drugs 0.000 abstract 1
- PAJMKGZZBBTTOY-ZFORQUDYSA-N treprostinil Chemical compound C1=CC=C(OCC(O)=O)C2=C1C[C@@H]1[C@@H](CC[C@@H](O)CCCCC)[C@H](O)C[C@@H]1C2 PAJMKGZZBBTTOY-ZFORQUDYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062968651P | 2020-01-31 | 2020-01-31 | |
| PCT/IB2021/000046 WO2021152398A1 (en) | 2020-01-31 | 2021-01-29 | Dosages and methods for treating pulmonary arterial hypertension with rodatristat |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022009254A true MX2022009254A (es) | 2022-09-07 |
Family
ID=75143674
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022009254A MX2022009254A (es) | 2020-01-31 | 2021-01-29 | Dosificacion y metodos para tratar la hipertension arterial pulmonar. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230074252A1 (https=) |
| EP (1) | EP4096633A1 (https=) |
| JP (1) | JP2023512025A (https=) |
| KR (1) | KR20220156813A (https=) |
| CN (1) | CN115379825A (https=) |
| AU (1) | AU2021212355A1 (https=) |
| CA (1) | CA3165432A1 (https=) |
| MX (1) | MX2022009254A (https=) |
| WO (1) | WO2021152398A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11413287B2 (en) | 2018-11-16 | 2022-08-16 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension |
| WO2023062595A1 (en) * | 2021-10-14 | 2023-04-20 | Altavant Sciences Gmbh | Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl |
| WO2023079486A1 (en) * | 2021-11-03 | 2023-05-11 | Altavant Sciences Gmbh | Treatment of pulmonary arterial hypertension with rodatristat and ambrisentan |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| CA3119912A1 (en) * | 2018-11-14 | 2020-05-22 | Altavant Sciences Gmbh | A crystalline spirocyclic compound inhibitor of tryptophan hydroxylase 1 (tph1) for treating diseases or disorders associated with peripheral serotonin |
-
2021
- 2021-01-29 CN CN202180021555.2A patent/CN115379825A/zh not_active Withdrawn
- 2021-01-29 WO PCT/IB2021/000046 patent/WO2021152398A1/en not_active Ceased
- 2021-01-29 AU AU2021212355A patent/AU2021212355A1/en not_active Abandoned
- 2021-01-29 KR KR1020227030098A patent/KR20220156813A/ko not_active Withdrawn
- 2021-01-29 EP EP21713735.5A patent/EP4096633A1/en not_active Withdrawn
- 2021-01-29 JP JP2022546019A patent/JP2023512025A/ja active Pending
- 2021-01-29 MX MX2022009254A patent/MX2022009254A/es unknown
- 2021-01-29 US US17/759,700 patent/US20230074252A1/en not_active Abandoned
- 2021-01-29 CA CA3165432A patent/CA3165432A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021152398A1 (en) | 2021-08-05 |
| EP4096633A1 (en) | 2022-12-07 |
| AU2021212355A1 (en) | 2022-08-18 |
| JP2023512025A (ja) | 2023-03-23 |
| CN115379825A (zh) | 2022-11-22 |
| CA3165432A1 (en) | 2021-08-05 |
| KR20220156813A (ko) | 2022-11-28 |
| US20230074252A1 (en) | 2023-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009254A (es) | Dosificacion y metodos para tratar la hipertension arterial pulmonar. | |
| US8034808B2 (en) | Therapeutic compositions containing at least one pyrrolobenzodiazepine derivative and fludarabine | |
| UA94427C2 (ru) | Фармацевтическая композиция для местного лечения неоваскулярных расстройств глаз | |
| CA2691914A1 (en) | Pharmaceutical compositions and methods of treating dry eye disorders | |
| CA2540858A1 (en) | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication | |
| GB0423653D0 (en) | Pharmaceutical compounds | |
| WO2007056075A3 (en) | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | |
| CA2405796A1 (en) | Methods and compositions for modulating alpha adrenergic receptor activity | |
| Drinane et al. | Sofosbuvir and ribavirin eradication of refractory hepatitis E in an immunosuppressed kidney transplant recipient | |
| NO20090068L (no) | Aktive agent formuleringer, fremstillingsmetoder, og anvendelsesmetoder | |
| CN101031305A (zh) | 类风湿性关节炎的预防和/或治疗药物 | |
| RU2010132580A (ru) | Способы и составы для лечения субарахноидального кровоизлияния коронарной и артериальной аневризмы | |
| JP2023512025A5 (https=) | ||
| Ramani et al. | Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension | |
| Shen et al. | Synergistic down-regulation of signal transduction and cytotoxicity by tiazofurin and quercetin in human ovarian carcinoma cells | |
| WO2020157577A8 (en) | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl | |
| Aribindi et al. | Investigational pharmacological agents for the treatment of ARDS | |
| Jenkins et al. | Public Interest Comment: Interagency Efforts to Develop the American Conservation and Stewardship Atlas | |
| CA2504665A1 (en) | Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia | |
| de Tejada Echanojáuregui et al. | Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant hepatitis B virus | |
| Maher et al. | Taxanes and capecitabine in combination: rationale and clinical results | |
| Sohn et al. | Cardiac morbidity in advanced chronic myelogenous leukaemia patients treated by successive allogeneic stem cell transplantation with busulphan/cyclophosphamide conditioning after imatinib mesylate administration | |
| Pickard et al. | Excellent Outcomes with Brentuximab-Nivolumab for Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma in the Real-World Setting | |
| Stornaiuolo et al. | Adefovir dipivoxil-associated thrombocytopenia in a patient with chronic hepatitis B | |
| Zomorodi et al. | Evaluation of the drug-drug interaction profile of vebicorvir, a first-generation hepatitis B core inhibitor: findings from phase 1 and phase 2a studies |